Zoe A. Efstathiadou

Dr. Zoe A. Efstathiadou

orcid

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2001 in European Journal of Endocrinology
Verified
Journal Article
Closed access
ZEZoe A. Efstathiadou
Zoe A. Efstathiadou
SBS Bitsis
S Bitsis
HMHj Milionis
Hj Milionis
AKA Kukuvitis
A Kukuvitis
EBEt Bairaktari
Et Bairaktari
ATA Tsatsoulis
A Tsatsoulis
OBJECTIVE: The significance of dyslipidemia in subclinical hypothyroidism (SH) and the effect of thyroid substitution on lipids remain controversial. The present study aimed to assess the association of SH with lipid abnormalities and to quantify the effect of L-thyroxine therapy on serum lipid profiles. DESIGN: Serum lipid parameters of 66 patients with SH and 75 age- and sex-matched euthyroid controls were evaluated in a cross-sectional study. RESULTS: Patients with SH had higher total cholesterol (TC) (222+/-45 (s.d.) vs 190+/- 32 mg/dl), low-density lipoprotein cholesterol (LDL-C) (139+/-28 vs 118+/-39 mg/dl), apolipoprotein B (149+/-21 vs 139+/-18 mg/dl) and lipoprotein (a) (Lp(a)) (median 12.5 (0.8-101) mg/dl vs 7 (0.8-44) mg/dl) levels compared with euthyroid controls (P<0.05 for all comparisons). In a follow-up study including 37 patients with SH, all measurements were repeated after restoration of a euthyroid state with incremental doses of l-thyroxine. No significant changes in serum lipid profiles were observed except for a decrease in high-density lipoprotein cholesterol (59+/-15 to 55+/-14 mg/dl, P or =240 mg/dl) showed a significant reduction in both TC (278+/-28 vs 257+/-36 mg/dl, P<0.05) and LDL-C (192+/-23 vs 173+/-28 mg/dl, P or =10 microU/ml. Thyroid autoimmunity had no effect on either the baseline or the post-treatment lipid profile. CONCLUSION: Although patients with subclinical hypothyroidism exhibit increased levels of the atherogenic parameters (mainly LDL-C and Lp(a)), thyroid substitution therapy does not seem to significantly improve dyslipidemia in the whole group of patients.

8 March 2008 in Journal of Cancer Research and Clinical Oncology
Verified
Journal Article
Closed access
PDF file
SPStergios A Polyzos
Stergios A Polyzos
MΚMarina Κita
Marina Κita
ZEZoe A. Efstathiadou
Zoe A. Efstathiadou
PPPavlos Poulakos
Pavlos Poulakos
ASAristidis Slavakis
Aristidis Slavakis
AAAvraam Avramidis
Avraam Avramidis

1 September 2001 in Journal of Bone and Mineral Research
Verified
Journal Article
Closed access
PDF file
ZEZoe A. Efstathiadou
Zoe A. Efstathiadou
ATAgathocles Tsatsoulis
Agathocles Tsatsoulis
JIJohn P. A. Ioannidis
John P. A. Ioannidis
Several studies have addressed the effect of the Sp1 polymorphism of the collagen Iα 1 (COLIA1) gene on the prevalence of fractures. The results are not in full agreement on whether this polymorphism is associated with fracture risk. To clarify this uncertainty, we performed a meta-analysis including 13 eligible studies with 3641 subjects. The COLIA1 Sp1 polymorphism showed a dose-response relationship with the prevalence of fractures. The risk was 1.25-fold (95% CI, 1.09–1.45) in Ss heterozygotes versus SS homozygotes, 1.68-fold (95% CI, 1.35–2.10) in ss homozygotes versus SS> homozygotes, and 1.35 (95% CI, 1.04–1.75) for ss homozygotes versus Ss heterozygotes by random effects calculations. There was modest heterogeneity for these three effect estimates (p value for heterogeneity, 0.17, 0.16, and 0.08, respectively). The Sp1 polymorphism effects possibly were larger when the analysis was limited to studies considering only vertebral fractures (pooled risk ratios [RR], 1.30, 2.07, and 1.46, respectively). Conversely, the Sp1 polymorphism effects tended to be smaller in studies with mean patient age ≥65 years than in studies with younger patients on average, but the differences were not formally significant. We estimated the total average attributable fraction (AF) of fractures due to the s allele in European/U.S. populations as 9.4%. The meta-analysis suggests an important role for the Sp1 polymorphism in the regulation of fracture risk; however, potential heterogeneity across ethnic groups, age groups, and skeletal sites may be important to clarify in future studies. Very large studies or meta-analyses are required to document subtle genetic differences in fracture risk.

9 December 2005 in Diabetologia
Verified
Journal Article
Closed access
PDF file
EKE. Kousta
E. Kousta
ZEZoe A. Efstathiadou
Zoe A. Efstathiadou
NLN. J. Lawrence
N. J. Lawrence
JJJ. A. R. Jeffs
J. A. R. Jeffs
IGI. F. Godsland
I. F. Godsland
DJD. G. Johnston
D. G. Johnston

1 May 2021 in Maturitas
Verified
Journal Article
Closed access
SPStergios A Polyzos
Stergios A Polyzos
AAAthanasios D. Anastasilakis
Athanasios D. Anastasilakis
ZEZoe A. Efstathiadou
Zoe A. Efstathiadou
MYMaria P. Yavropoulou
Maria P. Yavropoulou
Polyzois MakrasPolyzois Makras
Polyzois Makras

27 June 2015 in Pituitary
Verified
Journal Article
Closed access
PDF file
ZEZoe A. Efstathiadou
Zoe A. Efstathiadou
ABA. Bargiota
A. Bargiota
ACA. Chrisoulidou
A. Chrisoulidou
GKGeorge Kanakis
George Kanakis
LPL. Papanastasiou
L. Papanastasiou
STS. Tsagarakis
S. Tsagarakis